US-based healthcare AI company Akido Labs has raised $60m in a Series B funding round led by Oak HC/FT, with participation from Greco and SNR.
Existing investors Y Combinator, Future Communities Capital, Jeff Dean, and the Comprehensive Blood & Cancer Centre also participated in the funding round.
The funding will be utilised to expand the reach of ScopeAI, a system designed to enhance clinical capacity and improve healthcare access.
Oak HC/FT co-founder and managing partner Andrew Adams said: “Akido is delivering on the promise of changing how patients experience a visit with their provider through AI.
“With its robust, longitudinal dataset, Akido has the refinement in its foundational model to offer clinical accuracy where others have struggled.
“We are excited to partner with their exceptional team of healthcare and technical operators to scale ScopeAI, expanding access to high-quality, AI-powered care for more patients.”
ScopeAI is revolutionising the way Akido providers deliver healthcare, enabling them to manage a larger patient load without sacrificing quality.
The system integrates medical intelligence into clinical workflows, enhancing scale, efficiency, and consistency in patient care.
It guides the trained Medical Assistant (MA) during a visit using intelligent prompts to comprehensively assess the patient’s condition.
ScopeAI employs clinical reasoning to adapt in real-time, facilitating dynamic conversations while generating a complete clinical report.
The report includes a preliminary diagnosis, treatment plan, and justification log.
The system allows providers to gain a thorough understanding of a patient’s health with reduced time on documentation.
Providers using ScopeAI can oversee teams of MAs conducting visits, which increases healthcare access and allows providers to focus on more complex cases.
Akido’s AI-based healthcare visits have resulted in five times more face-to-face patient interaction and achieved a 96 NPS score.
The new funding will accelerate ScopeAI’s development across Akido Care’s network of 240 providers in 26 specialties.
The funding will also support Akido’s expansion into new markets, such as the innovative healthcare programme in New York City, focused on chronic diseases.
Akido co-founder and CEO Prashant Samant said: “We built ScopeAI to tackle the single biggest challenge facing healthcare systems worldwide: the physician shortage.
“With demand for care far exceeding supply, AI is the key to addressing the global doctor deficit, empowering healthcare providers, and ensuring patients receive the timely, high-quality care they deserve, regardless of financial means or geography.
“At Akido, we believe exceptional healthcare is a basic human right. Our work has always focused on democratising high-quality healthcare, and this funding enables us to accelerate that mission.”
